The prevalence of pre‐treatment and acquired HIV drug resistance in Vietnam: a nationally representative survey, 2017–2018
-
- Vu Quoc Dat
- Department of Infectious Diseases Hanoi Medical University Hanoi Vietnam
-
- Nguyen Thi Lan Anh
- National Institute of Hygiene and Epidemiology Hanoi Vietnam
-
- Khuu Van Nghia
- Pasteur Institute of Ho Chi Minh City Ho Chi Minh City Vietnam
-
- Nguyen Thuy Linh
- National Institute of Hygiene and Epidemiology Hanoi Vietnam
-
- Huynh Hoang Khanh Thu
- Pasteur Institute of Ho Chi Minh City Ho Chi Minh City Vietnam
-
- Tran Thi Minh Tam
- National Institute of Hygiene and Epidemiology Hanoi Vietnam
-
- Tran Ton
- Pasteur Institute of Ho Chi Minh City Ho Chi Minh City Vietnam
-
- Luong Que Anh
- Pasteur Institute of Ho Chi Minh City Ho Chi Minh City Vietnam
-
- Nguyen Duy Phuc
- Pasteur Institute of Ho Chi Minh City Ho Chi Minh City Vietnam
-
- Phan Thi Thu Huong
- Vietnam Administration for HIV/AIDS Control Hanoi Vietnam
-
- Do Thi Nhan
- Vietnam Administration for HIV/AIDS Control Hanoi Vietnam
-
- Nguyen Huu Hai
- Vietnam Administration for HIV/AIDS Control Hanoi Vietnam
-
- Silvia Bertagnolio
- World Health Organization Geneva Switzerland
-
- Amy M. Crisp
- Department of Biostatistics University of Florida Gainesville Florida USA
-
- Seth Inzaule
- World Health Organization Geneva Switzerland
-
- Natalie E. Dean
- Department of Biostatistics University of Florida Gainesville Florida USA
-
- Michael R. Jordan
- Division of Geographic Medicine Tufts Medical Center Boston Massachusetts USA
-
- Van Thi Thuy Nguyen
- World Health Organization Vietnam Country Office Hanoi Vietnam
抄録
<jats:title>Abstract</jats:title><jats:sec><jats:title>Introduction</jats:title><jats:p>Monitoring the population‐level emergence and transmission of HIV drug resistance (HIVDR) is necessary for supporting public health programmes. This study provides a nationally representative prevalence estimate of HIVDR in people initiating antiretroviral therapy (ART) and estimates of acquired HIVDR and viral load (VL) suppression in people who have received it for 12 or ≥48 months in Vietnam.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>The study was conducted between September 2017 and March 2018 following World Health Organization guidance. Thirty ART clinics were randomly sampled using probability proportional to size sampling from a total of 367 ART clinics in the country.</jats:p></jats:sec><jats:sec><jats:title>Results and Discussion</jats:title><jats:p>In total, 409 patients initiating ART were enrolled into the survey of pre‐treatment HIVDR. The prevalence of any pre‐treatment HIVDR was 5.8% (95% CI 3.4–9.5%), and the prevalence of non‐nucleoside reverse transcriptase inhibitor resistance was 3.4% (95% CI 1.8–6.2%). Four hundred twenty‐nine patients on ART for 12±3 months and 723 patients on ART for ≥48 months were enrolled into the surveys of acquired HIVDR. The prevalence of VL suppression (defined as <1000 copies/ml) in patients on ART for 12±3 and ≥48 months was 95.5% (95% CI 91.3–97.8%) and 96.1% (95% CI 93.2–97.8%), respectively. Among individuals with viral non‐suppression, any HIVDR was detected in 11/14 (weighted prevalence 74.3%) of those on ART for 12±3 months and in 24/27 (weighted prevalence 88.5%) of those receiving ART for ≥48 months.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>This nationally representative study of HIVDR found high levels of VL suppression among those on ART for 12 and ≥48 months. Overall, high levels of VL suppression at both time points suggested good adherence among patients receiving ART and quality of treatment services in Vietnam.</jats:p></jats:sec><jats:sec><jats:title>Clinical Trial Number</jats:title><jats:p>Not applicable</jats:p></jats:sec>
収録刊行物
-
- Journal of the International AIDS Society
-
Journal of the International AIDS Society 25 (2), 2022-02
Wiley